Organon falls on halting development of endometriosis pain drug

Shares of women's healthcare firm Organon OGN.N fall 2.9% to $9.79 before the bell

OGN says it will discontinue the development of its experimental drug, after it failed to reduce pain in women suffering from endometriosis in a proof-of-concept mid-stage study

Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, often causing chronic pelvic pain and infertility

The drug, OG-6219, was being tested in women aged 18 to 49 who had moderate-to-severe endometriosis-related pain, but results showed no significant improvement compared to a placebo

Patients were randomized to receive one of three doses of OG-6219 or placebo orally twice a day - OGN

Up to last close, stock down 32.6% YTD